GHK-Cu: What the Research on the Copper Tripeptide Actually Shows, and How Topical and Injectable Research Differ

Few research peptides attract as much attention from outside the laboratory as GHK-Cu, and few have a literature so dominated by a single research group. This article separates what has been measured from what is marketed: the models used, the endpoints reported, the gap where clinical evidence should be, and the difference between a notified cosmetic ingredient and a research reagent in a vial.

What is GHK-Cu?

GHK is the tripeptide glycyl-L-histidyl-L-lysine. It occurs naturally in human plasma, saliva and urine, and it binds copper(II) with an affinity comparable to the copper transport site on albumin, forming the complex written as GHK-Cu. The 2008 review by Pickart in the Journal of Biomaterials Science reports that plasma levels decline with age, which is one reason the peptide entered the ageing conversation.

Commercially, GHK-Cu appears in two very different forms: as copper tripeptide-1 in cosmetic products, and as a lyophilised research reagent in vials of 50 mg or 100 mg. The chemistry is the same; the regulatory status, the manufacturing controls and the evidence base for each form are not.

What has the research measured in skin and tissue models?

Most of the literature is preclinical. The 2008 review collects cell and animal work describing chemoattraction of repair cells, changes in cytokine and growth factor expression, increased synthesis of collagen, elastin and glycosaminoglycans, and proliferation of fibroblasts and keratinocytes in culture and in wound models. A 2018 review by the same author in the International Journal of Molecular Sciences added gene-expression data from the Broad Institute's Connectivity Map, proposing that GHK modulates a large number of genes.

A 2023 study in the Journal of Cosmetic Dermatology tested GHK-Cu together with hyaluronic acid in human dermal fibroblasts and in an ex vivo skin model, reporting increased expression of collagen I, IV and VII, with the strongest effect on collagen IV at a specific ratio. Note the models: cultured fibroblasts and excised skin, funded by ingredient manufacturers. These are legitimate cosmetic-science results; they are not outcomes in living people.

Where is the clinical evidence gap?

A 2024 review in BioImpacts on topically applied GHK reaches an unusually candid conclusion for a cosmetic-ingredient review: cellular studies support GHK as an anti-wrinkle ingredient, GHK-Cu and palmitoyl-GHK are widely used in products, and yet there is "a surprising absence of clinical studies" using them. The review also flags skin permeability as an unresolved problem for a hydrophilic peptide, which is why formulation strategies such as metal complexation, lipidation and microneedling are discussed at all.

Two further cautions apply when reading this literature. Much of it is written or co-written by Loren Pickart, who discovered the peptide and runs a company selling GHK products, so the reviews summarise a body of work with an interested author. And most primary studies used topical or in vitro exposure; studies of injected GHK-Cu in people do not exist in the published record, so questions about an injectable route cannot be answered from evidence.

Is topical GHK-Cu the same as the research vial?

Chemically yes, legally and practically no. In the EU, copper tripeptide-1 is listed in the CosIng ingredient database with a skin-conditioning function, and finished cosmetic products containing it must be notified, safety assessed and labelled under Regulation (EC) 1223/2009 before sale. That route covers creams and serums applied to intact skin, with claims limited to cosmetic effects.

A research vial is a laboratory reagent supplied for in vitro and preclinical work. It is not a cosmetic, because it is not a finished product placed on the market for application to the body, and it is not a medicine, because it is not presented for treating or modifying a physiological function in people. That status holds only while the presentation stays within research use; a vendor that markets a research vial for use on or in people is presenting an unlicensed medicine or an unnotified cosmetic, and regulators treat it as such.

How is GHK-Cu handled and verified in a laboratory?

GHK-Cu ships as a blue to blue-violet lyophilised powder that is hygroscopic and light sensitive. Vials stay sealed, dry and refrigerated until use; after reconstitution with bacteriostatic water the solution is kept at 2 to 8 °C and discarded if the colour shifts or particles appear. The general handling rules are in our storage guide and reconstitution guide.

Verification is the same as for any research peptide: a batch reference on the vial, an independent laboratory report showing identity and HPLC purity, and a link to the laboratory's own verification page. Vitality Peps supplies GHK-Cu as a 100 mg vial and a pre-filled pen, each with its current Janoshik report on the lab results page.

How should you evaluate a GHK-Cu source?

Apply four checks. Does the seller publish a batch-level report you can verify with the laboratory? Does it state where stock is held and ship from inside the EU? Does its language stay within research use, without appearance or health promises? Does it show a company address and accept payment methods you could dispute? A supplier that fails the last two is telling you how it will behave when something goes wrong. Our 12-point vendor checklist expands each check.

For laboratory research use only. Not for human or veterinary consumption. This article summarises published research and regulatory status; it does not describe an approved or recommended use of any compound.

Frequently asked questions

Will over-the-counter copper peptide serums give the same results as an injectable research vial?

The published evidence does not answer that question, because there are no controlled human studies comparing the two and very few clinical studies of GHK-Cu products at all. The cosmetic literature deals with skin penetration of topical GHK; the research vial is a reagent for laboratory models, not a product with a studied human route.

Can I make my own topical serum from a research vial?

A research-use vial is supplied as a laboratory reagent, not as a cosmetic ingredient. In the EU a cosmetic product must be notified, safety assessed and labelled under Regulation 1223/2009 before it is placed on the market, and home preparations from reagents sit outside that system. Notified cosmetic products containing copper tripeptide-1 exist for that purpose.

Does the copper matter, or is plain GHK enough?

The literature studies both. GHK binds copper with an affinity similar to albumin's copper site, and reviews describe the copper complex and the free tripeptide as acting through overlapping pathways. Which form a laboratory uses depends on the model and the question; the reviews are largely authored by the peptide's discoverer, which is worth knowing when weighing them.

How do I reconstitute a 50 mg or 100 mg GHK-Cu vial?

As a laboratory reagent: bacteriostatic water added slowly down the vial wall, gentle swirling, then refrigerated storage. The volume depends on the concentration a protocol needs; our reconstitution guide and calculator show the arithmetic without recommending any use in people.

Is GHK-Cu legal in the EU?

As a cosmetic ingredient, copper tripeptide-1 appears in the EU CosIng database and is used in notified products. As a research reagent it is sold for laboratory use only. There is no marketing authorisation for GHK-Cu as a medicine, so presenting it for human use in any other form would make it an unlicensed medicine.

Why is a GHK-Cu solution blue?

The colour comes from the copper(II) ion bound to the tripeptide. A blue to blue-violet solution is expected; a colour change, cloudiness or particles after storage are reasons to discard the vial rather than use it.

Sources

• Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. https://doi.org/10.1163/156856208784909435
• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. https://doi.org/10.3390/ijms19071987
• Jiang F et al. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. Journal of Cosmetic Dermatology, 2023. https://doi.org/10.1111/jocd.15763
• Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts, 2024. https://doi.org/10.34172/bi.30071
• Regulation (EC) No 1223/2009 on cosmetic products. EUR-Lex
• European Commission, CosIng database entry for Copper Tripeptide-1. ec.europa.eu

Journal references were retrieved from PubMed.

Related reading

• How to read a peptide certificate of analysis without overinterpreting purity
• Why promising peptide studies fail to translate from animals to humans
• Bacteriostatic water vs sterile water for reconstituting peptides